Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Nathaniel E. Wiest, Umair Majeed, Karan Seegobin, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21

Showing 21 citing articles:

Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 27
Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review
Chiara Pozzessere, Bianca Mazini, Patrick Omoumi, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2585-2585
Open Access | Times Cited: 7
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 11
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
Martin Sattler, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1936-1936
Open Access | Times Cited: 10
Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations
Elodie Long‐Mira, Christophe Bontoux, Guylène Rignol, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1034-1034
Open Access
Lung cancer: Current status of preclinical research
Emmanuel Boadi Amoafo, Elizabeth Twum, Bismarck Afedo Hottor, et al.
Elsevier eBooks (2025), pp. 95-114
Closed Access
Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
Zhuo Chen, J. Gong, Jing Chen, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer
Lan Sun, Lingyue Gao, Yingxi Zhao, et al.
Recent Patents on Anti-Cancer Drug Discovery (2022) Vol. 18, Iss. 4, pp. 506-516
Closed Access | Times Cited: 12
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study
Xiaoyan Yin, Xinchao Liu, Fei Ren, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 7
Open Access | Times Cited: 2
Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
Cecilia Hes, R. Thomas Jagoe
BJC Reports (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 4
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer
Ibrahim M. Abbass, Daniel Sheinson, Anuj Shah, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 7, pp. 649-659
Closed Access | Times Cited: 1
Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
João Queirós Coelho, Joana Sobrinho Simões, Tomás Fonseca, et al.
Acta Médica Portuguesa (2024)
Open Access | Times Cited: 1
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer
Rudolf M. Huber, Diego Kauffmann‐Guerrero
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
Soojin Jun, Sehhoon Park, Jong‐Mu Sun, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5450-5450
Open Access | Times Cited: 3
Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study
Kan Jiang, Lin Wu, Xinlong Zheng, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access
Immunotherapy with Checkpoint Inhibitors

(2024), pp. 253-299
Closed Access
Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
Pengcheng Zhu, Zhitong Li, Yuxiang Sun, et al.
Cancer Science (2024)
Open Access
Advances in Targeted Therapy of Non-small Cell Lung Cancer with EGFR Combined With P53 Gene Mutation
Di Lu, Yueyong Li, Ju Liao, et al.
Journal of Clinical Medicine Research (2024) Vol. 5, Iss. 2, pp. 231-231
Open Access
Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
Shengjie Sun, Jindi Han, Wei Liu, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 18, pp. 6069-6081
Open Access | Times Cited: 2
Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-Tyrosine Kinase Inhibitors: A Retrospective Dual-Center Study
Kan Jiang, Lin Wu, Xinlong Zheng, et al.
Research Square (Research Square) (2023)
Open Access
Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges
Mina Hosseini, Nima Rezaei
(2022), pp. 103-137
Closed Access
Page 1

Scroll to top